Foghorn Therapeutics reported a significant increase in collaboration revenue for the third quarter of 2026, primarily driven by non-recurring accounting adjustments following program reprioritizations. The company transitioned to a net income position and maintained a robust balance sheet to fund clinical development through late 2029.

Key Highlights

  • Collaboration revenue rose to $83.5 million, compared to $8.2 million in the prior year, due to a $74.1 million cumulative catch-up adjustment.
  • Total cash, cash equivalents, and marketable securities reached $156.2 million, providing an operational runway into the second half of 2029.
  • Development of the novel oral I&I program for IBD remains on track, with first-in-human trials targeted to begin by the end of 2027.